Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03900624|
Recruitment Status : Enrolling by invitation
First Posted : April 3, 2019
Last Update Posted : September 10, 2021
|Condition or disease||Intervention/treatment||Phase|
|Asthma Childhood||Drug: Dexamethasone||Phase 4|
As the pathophysiology of an acute asthma exacerbation is dysregulated inflammatory pathways, standard treatment includes the prompt initiation of intravenous systemic corticosteroids. Corticosteroids reduce the production of many mediators involved in the inflammatory process and inhibit macrophages, monocytes, T-lymphocytes, eosinophils, and basophils, which are activated during this process. Furthermore, corticosteroids improve the efficacy of beta-2 agonists, such as albuterol, a nebulized medication used for bronchodilation in acute asthma exacerbations. There remains an ongoing dialogue among the expert medical community regarding the superiority of specific IV corticosteroid, dosing, route and delivery. This debate continues secondary to a lack of definitive comparative data in the literature. While the benefits of receiving systemic corticosteroids has been demonstrated in multiple studies, to date, no head-to-head trials have been conducted comparing IV systemic corticosteroids in the PICU setting (DM vs. MP).
While several systemic corticosteroids are FDA approved for the treatment of asthma exacerbation including prednisone, prednisolone, MP and DM, the standard practice in PICU-level care is IV MP every 6 hours until enteral medications can be safely tolerated. Recent data from emergency room literature would suggest there is equipoise in use of dexamethasone as an alternative for methylprednisolone due to its increased glucocorticoid (anti-inflammatory) potency. Steroid agents are chosen at the discretion of clinical providers based upon a child's capacity to tolerate enteral medications and the specific clinical setting (outpatient vs. general inpatient vs. critical inpatient).
The investigators have performed a retrospective study over a 2-year period to assess if differences in clinical outcomes or adverse events exist in cohorts defined by DM exposure in the ER. Their data revealed no differences, but most children were switched to MP during their PICU stay making data analyses severely confounded by exposure to the defining characteristics of the comparative cohort. The investigators seek to first prospectively consent individuals to receive DM during their PICU asthma treatment and compare outcomes to PICU asthmatics concurrently admitted to the PICU receiving local standard care (MP). JHACH admits approximately 150 asthmatics per year in the PICU and the investigators hope to enroll up to 50 subjects into a DM only arm. The comparative standard care arm will be assessed at the end of the study period. Primary outcomes include (1) PICU Length of Stay, (2) Continuous nebulized albuterol duration, and (3) a composite outcome including use of non-invasive ventilation (NIV), terbutaline, inhaled helium, inhaled anesthetic gas, mechanical ventilation, and extracorporeal life support. This research will provide the needed epidemiologic and basic comparative data required to power and conduct a definitive, head-to-head trial of DM vs. MP.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Single Arm Treatment Group with a Prospective, Comparative Cohort Receiving Standard Care|
|Masking:||None (Open Label)|
|Official Title:||Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care Unit|
|Actual Study Start Date :||May 21, 2019|
|Estimated Primary Completion Date :||May 21, 2022|
|Estimated Study Completion Date :||July 21, 2022|
No Intervention: Methylprednisolone Arm
Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
Experimental: Dexamethasone Arm
Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticu
- PICU Length of Stay [ Time Frame: through study completion, approximately 1-year from enrollment ]Pediatric intensive care unit length of stay
- Duration of continuous nebulized albuterol [ Time Frame: through study completion, approximately 1-year from enrollment ]Duration of continuous nebulized albuterol
- Composite Outcome of Adjunctive Asthma Therapy [ Time Frame: through study completion, approximately 1-year from enrollment ]use of non-invasive ventilation (NIV), terbutaline, inhaled helium, inhaled anesthetic gas, mechanical ventilation, and extracorporeal life support
- Hospital Readmissions [ Time Frame: Within 30 days of hospital discharge ]Within 30-day same cause hospital readmission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03900624
|United States, Florida|
|Johns Hopkins All Children's Hospital|
|Saint Petersburg, Florida, United States, 33701|
|Principal Investigator:||Anthony A Sochet, MD, MS||Johns Hopkins All Children's Hospital|